Page last updated: 2024-12-11

vicenistatin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

vicenistatin: a macrocyclic lactam from Streptomyces sp. HC34; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6438888
CHEMBL ID1797115
CHEBI ID80023
MeSH IDM0220474

Synonyms (16)

Synonym
nsc-641691
vicenistatine
vicenistatin
150999-05-6
(3e,5e,7s,8s,10e,13e,15e,19s)-8-[(2r,4s,5s,6r)-4-hydroxy-6-methyl-5-(methylamino)oxan-2-yl]oxy-7,11,13,19-tetramethyl-1-azacycloicosa-3,5,10,13,15-pentaen-2-one
chebi:80023 ,
CHEMBL1797115
unii-yyz37b8vcv
yyz37b8vcv ,
1-azacycloeicosa-3,5,10,13,15-pentaen-2-one, 7,11,13,19-tetramethyl-8-((2,4,6-trideoxy-4-(methylamino)hexopyranosyl)oxy)-
7,11,13,19-tetramethyl-8-((2,4,6-trideoxy-4-(methylamino)hexopyranosyl)oxy)-1-azacycloeicosa-3,5,10,13,15-pentaen-2-one
Q15991363
(3e,5e,7s,8s,10e,13e,15e,19s)-8-{[(2r,4s,5s,6r)-4-hydroxy-6-methyl-5-(methylamino)oxan-2-yl]oxy}-7,11,13,19-tetramethyl-1-azacycloicosa-3,5,10,13,15-pentaen-2-one
(3e,5e,7s,8s,10e,13e,15e,19s)-7,11,13,19-tetramethyl-8-[[2,4,6-trideoxy-4-(methylamino)-beta-d-ribo-hexopyranosyl]oxy]azacycloeicosa-3,5,10,13,15-pentaen-2-one
azacycloeicosa-3,5,10,13,15-pentaen-2-one, 7,11,13,19-tetramethyl-8-[[2,4,6-trideoxy-4-(methylamino)-beta-d-ribo-hexopyranosyl]oxy]-, (3e,5e,7s,8s,10e,13e,15e,19s)-
DTXSID701031592
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
lactamCyclic amides of amino carboxylic acids, having a 1-azacycloalkan-2-one structure, or analogues having unsaturation or heteroatoms replacing one or more carbon atoms of the ring.
azamacrocycleA cyclic macromolecule containing one or more nitrogen atoms in place of carbon either as the divalent group NH for the group CH2 or a single trivalent nitrogen atom for the group CH.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (24)

Assay IDTitleYearJournalArticle
AID1825299Antibacterial activity against Helicobacter pylori 159 assessed as bacterial growth inhibition
AID602972Growth inhibition of Artemia salina assessed as mortality rate at 10 ug/ml after 24 hrs by microscopy2011Bioorganic & medicinal chemistry letters, 07-01, Volume: 21, Issue:13
RETRACTED: Sannastatin, a novel toxic macrolactam polyketide glycoside produced by actinomycete Streptomyces sannanensis.
AID1825309Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay
AID1825293Antibacterial activity against methicillin-resistant Staphylococcus aureus 745524 assessed as bacterial growth inhibition
AID1825300Antifungal activity against Candida albicans C5 assessed as fungal growth inhibition
AID1825291Antibacterial activity against methicillin-resistant Staphylococcus aureus shhs-E1 assessed as bacterial growth inhibition
AID1825297Antibacterial activity against Mycobacterium smegmatis ATCC607 assessed as bacterial growth inhibition
AID1825301Antifungal activity against Candida albicans ATCC SC5314 assessed as fungal growth inhibition
AID1825307Cytotoxicity against human RKO cells assessed as reduction in cell viability after 72 hrs by MTT assay
AID1825289Antibacterial activity against Micrococcus luteus ML01 assessed as bacterial growth inhibition
AID1825304Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
AID1825303Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
AID1825302Antifungal activity against Cryptococcus neoformans ATCC4906 assessed as fungal growth inhibition
AID1825298Antibacterial activity against Helicobacter pylori G27 assessed as bacterial growth inhibition
AID1825305Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay
AID1825308Cytotoxicity against human HL-60 cells assessed as reduction in cell viability after 72 hrs by MTT assay
AID1825290Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as bacterial growth inhibition
AID1825306Cytotoxicity against human A549 cells assessed as reduction in cell viability by after 72 hrs MTT assay
AID1825295Antibacterial activity against methicillin-resistant Staphylococcus aureus 718306 assessed as bacterial growth inhibition
AID1825310Cytotoxicity against human BEAS-2B cells assessed as reduction in cell viability after 72 hrs by MTT assay
AID1825296Antibacterial activity against methicillin-resistant Staphylococcus aureus 6917 assessed as bacterial growth inhibition
AID1825288Antibacterial activity against Bacillus subtilis BS01 assessed as bacterial growth inhibition
AID1825292Antibacterial activity against methicillin-resistant Staphylococcus aureus 16339 assessed as bacterial growth inhibition
AID1825294Antibacterial activity against methicillin-resistant Staphylococcus aureus 16162 assessed as bacterial growth inhibition
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (9.52)18.2507
2000's8 (38.10)29.6817
2010's8 (38.10)24.3611
2020's3 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.18 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.97 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (9.52%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (90.48%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]